Medtronic recently announced that it received clearance from the FDA and CE Mark approval for its LINQ II insertable cardiac monitor (ICM). The announcement notes that ICMs “are small, subcutaneously ...
Medtronic this week received regulatory approval for use of an implantable cardiac monitor in pediatric patients, giving doctors and parents greater peace of mind about the device's safety. On Tuesday ...
The LINQ II ICM is the first continuous, long-term cardiac monitor cleared by FDA for the pediatric patient population The LINQ II system is a small (one-third the size of a AAA battery), wireless ICM ...
Medtronic plc MDT recently announced the receipt of the FDA approval and the CE Mark for its LINQ II insertable cardiac monitor (“ICM”) with remote programming. Notably, ICM is a new long-term ...
Medtronic developed a way to reduce false alerts through its AccuRhythm™ AI algorithms. The algorithm is applied through cloud-based updates to all LINQ II™ Insertable Cardiac Monitors (ICMs) and ...
Medtronic said its AccuRhythm AI algorithm technology is the winner of the 7 th annual MedTech Breakthrough Awards program as the "Best New Monitoring Solution." AccuRhythm AI is an artificial ...
Next Generation ICM Offers Remote Programming with Improved Longevity and Enhanced Accuracy DUBLIN, July 07, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, ...
Medtronic plc MDT recently announced the receipt of the FDA approval and the CE Mark for its LINQ II insertable cardiac monitor (“ICM”) with remote programming. Notably, ICM is a new long-term ...
DUBLIN, July 07, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback